


Research identifies new information to accelerate structure-based drug design against COVID-19

7 October 2020




Structure of SARS-CoV-2 Main protease: (2) Crystals of CoVID-19 free enzyme - picture 1 of crystals picture shows image of Steve representation with all the fragments spattered on it. Credit: Diamond Light Source

A new paper in *Nature Communications* outlines how an international research team has identified potential ways forward to rapidly design improved and more potent compounds in the fight against COVID-19. The work is the result of a massive fragment screening effort to develop an antiviral targeting the SARS-CoV-2 main protease. The project was led by Martin Walsh, Deputy Life Sciences Director at Diamond Light Source; Frank von Delft, Professor of Structural Chemical Biology at the University of Oxford and Principal Beamline Scientist of I04-1/XChem at Diamond; and Nir London, Assistant Professor at the Weizmann Institute Israel. The team combined mass spectrometry with the XChem facility at Diamond, the UK's national synchrotron, to rapidly identify new lead compounds for drug development to treat

COVID-19.

For this study, called Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main [protease](#), the team probed an essential enzyme of SARS-CoV-2 with over 1,250 unique small compound, termed fragments, and identified 74 high-value fragment hits which can be used to develop new inhibitors for this essential viral protein. The paper details the data along with proposed design routes for progressing towards improved, more potent, compounds.

"COVID-19, caused by SARS-CoV-2, lacks effective therapeutics. Additionally, no [antiviral drugs](#) or vaccines were developed against the closely related coronavirus, SARS-CoV-1 or MERS-CoV, despite previous zoonotic outbreaks. To identify starting points for such therapeutics, we performed a large-scale screen of electrophile and non-covalent fragments through a combined [mass spectrometry](#) and X-ray approach against the SARS-CoV-2 main protease, one of two cysteine viral proteases essential for viral replication. Our crystallographic screen identified 74 hits that span the entire active site, as well as three hits at the dimer interface. These structures reveal routes to rapidly develop more potent inhibitors and offer unprecedented structural and reactivity information for on-going structure-based drug design against SARS-CoV-2 main protease," explains Martin Walsh who is addition to his role at Diamond is also a Medical Research Council (MRC) funded Research Group Leader at the Research Complex at Harwell (RCaH).



modern drug discovery, using small collections (100 s or 1000 s) of small compounds (

Structure of SARS-CoV-2 Main protease: (1) Crystals of CoVID-19 free enzyme - Steve representation with all the fragments spattered on it. Credit: Diamond Light Source

Structural biology, which can play a key role in drug development, was also rapidly deployed after the 2002 SARS-CoV-1 outbreak, with earlier work by the Hilgenfeld group on the main protease of coronarviruses leading to crystal structures of SARS-CoV-1 protease and inhibitor complexes. Other studies have taken the popular approach of a high-throughput screens (HTS) using very large compound libraries, followed by structural studies to elucidate the binding mode.

"Despite these efforts, drugs remain elusive that directly target SARS-CoV-2 (rather than disease symptoms) and are verified by clinical trials. In retrospect, this is perhaps unsurprising for the main protease inhibitors, as both peptidomimetic and covalent inhibition carry risks as strategies for drug development; in general, the simpler the molecule the lower the risk. We, therefore, applied a different approach to this protease, using fragment screening by high-throughput [structural biology](#)," adds Martin Walsh.

Fragment methods have become a staple of

APA citation: Research identifies new information to accelerate structure-based drug design against COVID-19 (2020, October 7) retrieved 30 April 2021 from <https://medicalxpress.com/news/2020-10-structure-based-drug-covid-.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.